Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiskie līdzekļi - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - elpceļu sindciālu vīrusu infekcijas - vakcīnas - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. skatīt nodaļas 4. 2 un 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.

Latvija - latviešu - Zāļu valsts aģentūra

grindeks, as, latvia - memantīna hidrohlorīds - apvalkotā tablete - 10 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - gliklazīds - modificētās darbības tablete - 60 mg

Latvija - latviešu - Zāļu valsts aģentūra

gedeon richter plc., hungary - levonorgestrels - mutē disperģējamā tablete - 1,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

lupin (europe) limited, united kingdom - gliklazīds - ilgstošās darbības tabletes - 60 mg

Latvija - latviešu - Zāļu valsts aģentūra

teva b.v., netherlands - moksonidīns - apvalkotā tablete - 0,4 mg

Latvija - latviešu - Zāļu valsts aģentūra

zentiva, k.s., czech republic - losartanum kalicum, hydrochlorothiazidum - apvalkotā tablete - 50 mg/12,5 mg

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

intervet international bv, nīderlande - dzīvas novājinātas mycoplasma synoviae celma ms1 - liofilizāts suspensijas pagatavošanai - vistas

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

fatro s.p.a., itālija - flumequine - pulveris iekšķīgai lietošanai - 500 mg/g - putni; zivis